🇺🇸 FDA
Patent

US 10869863

Multi-arm polymeric targeting anti-cancer conjugate

granted A61KA61K31/4745A61K47/545

Quick answer

US patent 10869863 (Multi-arm polymeric targeting anti-cancer conjugate) held by BrightGene Bio-Medical Technology Co., Ltd. expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BrightGene Bio-Medical Technology Co., Ltd.
Grant date
Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/4745, A61K47/545, A61K47/58, A61K47/60